251 related articles for article (PubMed ID: 34105499)
1. [Efficacy and Safety of PEG-rhG-CSF in HSC Mobilization in 71 Normal Healthy Donors for Allogeneic Hematopoietic Stem Cell Transplantation].
Liu F; He GC; Yi H; Li YC; Zhang S; Deng R; Deng Y; Lai SH; Su Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Jun; 29(3):951-956. PubMed ID: 34105499
[TBL] [Abstract][Full Text] [Related]
2. [Clinical Analysis of PEG-rhG-CSF in Mobilization of Autologous Hematopoietic Stem Cells in Hematological Tumors].
Chen QJ; Zheng XQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):556-560. PubMed ID: 38660866
[TBL] [Abstract][Full Text] [Related]
3. [A Single-Center Analysis of the Use of G-CSF Combined with Plerixafor to Mobilize Peripheral Blood Hematopoietic Stem Cell from Healthy Related Donors in Allogeneic Hematopoietic Stem Cell Transplantation].
Chen J; Yuan LL; Zhang X; Qiao JL; Yin QX; Zhang YM; Yang XL; Cao XY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):286-291. PubMed ID: 35123641
[TBL] [Abstract][Full Text] [Related]
4. High-versus standard-dose filgrastim (rhG-CSF) for mobilization of peripheral-blood progenitor cells from allogeneic donors and CD34(+) immunoselection.
Engelhardt M; Bertz H; Afting M; Waller CF; Finke J
J Clin Oncol; 1999 Jul; 17(7):2160-72. PubMed ID: 10561272
[TBL] [Abstract][Full Text] [Related]
5. Biosimilar Filgrastim (Tevagrastim, XMO2) for Allogeneic Hematopoietic Stem Cell Mobilization and Transplantation in Patients with Acute Myelogenous Leukemia/Myelodysplastic Syndromes.
Danylesko I; Sareli R; Bloom-Varda N; Yerushalmi R; Shem-Tov N; Shimoni A; Nagler A
Biol Blood Marrow Transplant; 2016 Feb; 22(2):277-283. PubMed ID: 26343949
[TBL] [Abstract][Full Text] [Related]
6. [CD34+ cell dose and hematologic recovery in allogeneic peripheral blood stem cell transplantation].
Sawada H; Wake A; Yamasaki Y; Izumi Y
Rinsho Ketsueki; 2000 Jun; 41(6):500-6. PubMed ID: 10921350
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic blood stem cell transplantation: peripheralization and yield of donor-derived primitive hematopoietic progenitor cells (CD34+ Thy-1dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease.
Körbling M; Huh YO; Durett A; Mirza N; Miller P; Engel H; Anderlini P; van Besien K; Andreeff M; Przepiorka D; Deisseroth AB; Champlin RE
Blood; 1995 Oct; 86(7):2842-8. PubMed ID: 7545476
[TBL] [Abstract][Full Text] [Related]
8. Donor lymphocyte apheresis for adoptive immunotherapy compared with blood stem cell apheresis.
Körbling M; Giralt S; Khouri I; Mirza N; Donato M; Anderlini P; Fischer H; Andreeff M; McMannis J; Champlin R
J Clin Apher; 2001; 16(2):82-7. PubMed ID: 11746533
[TBL] [Abstract][Full Text] [Related]
9. [Comparative study on the efficacy and safety between pegfilgrastim (PEG-rhG-CSF) and recombinant human granulocyte colony-stimulating factor in promoting hematopoietic recovery after allogeneic hematopoietic stem cell transplantation after hematological malignancy].
Yang F; Sun XD; Yuan L; Zhang JC; Hu JW; Liu N; Lou X; Su YF; Yu ZY; Chen JL; Li YH; Hu LD; Chen H; Jiang M
Zhonghua Xue Ye Xue Za Zhi; 2017 Oct; 38(10):831-836. PubMed ID: 29166733
[No Abstract] [Full Text] [Related]
10. Allogeneic stem cell transplantation with peripheral blood stem cells mobilized by pegylated G-CSF.
Hill GR; Morris ES; Fuery M; Hutchins C; Butler J; Grigg A; Roberts A; Bradstock K; Szer J; Kennedy G; Morton J; Durrant S
Biol Blood Marrow Transplant; 2006 Jun; 12(6):603-7. PubMed ID: 16737933
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic Hematopoietic Stem Cell Transplantation Mobilized With Pegylated Granulocyte Colony-Stimulating Factor Ameliorates Severe Acute Graft-Versus-Host Disease Through Enrichment of Monocytic Myeloid-Derived Suppressor Cells in the Graft: A Real World Experience.
Li L; Yin J; Li Y; Wang C; Mao X; Wei J; Cao Y; Wang N; Lin L; Xu J; Zhang Y
Front Immunol; 2021; 12():621935. PubMed ID: 33912154
[TBL] [Abstract][Full Text] [Related]
12. Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function.
Alexander ET; Towery JA; Miller AN; Kramer C; Hogan KR; Squires JE; Stuart RK; Costa LJ
Transfusion; 2011 Sep; 51(9):1995-2000. PubMed ID: 21392017
[TBL] [Abstract][Full Text] [Related]
13. Plerixafor on demand in ten healthy family donors as a rescue strategy to achieve an adequate graft for stem cell transplantation.
Gattillo S; Marktel S; Rizzo L; Malato S; Malabarba L; Coppola M; Assanelli A; Milani R; De Freitas T; Corti C; Bellio L; Ciceri F
Transfusion; 2015 Aug; 55(8):1993-2000. PubMed ID: 25721167
[TBL] [Abstract][Full Text] [Related]
14. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.
Nademanee AP; DiPersio JF; Maziarz RT; Stadtmauer EA; Micallef IN; Stiff PJ; Hsu FJ; Bridger G; Bolwell BJ
Biol Blood Marrow Transplant; 2012 Oct; 18(10):1564-72. PubMed ID: 22683613
[TBL] [Abstract][Full Text] [Related]
15. Analysis of stem cell apheresis products using intermediate-dose filgrastim plus large volume apheresis for allogeneic transplantation.
Engelhardt M; Bertz H; Wäsch R; Finke J
Ann Hematol; 2001 Apr; 80(4):201-8. PubMed ID: 11401085
[TBL] [Abstract][Full Text] [Related]
16. [DA-EPOCH Chemotherapy Combined with G-CSF Effectively Mobilizes Autologous PBHSC in NHL Patients].
Liao LS; Wei TN; Zheng ZH; Qu S; Xie Y; Wang ZH; Chen BY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Dec; 25(6):1670-1674. PubMed ID: 29262895
[TBL] [Abstract][Full Text] [Related]
17. [Differential regulation of CCR5 expression on T lymphocytes in healthy donors after mobilization with rhG-CSF and its correlation with aGVHD].
Wang M; Ma XJ; Dong YJ; Qiu ZX; Liu W; Li Y; Wang MJ; Sun YH; Ren HY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Aug; 21(4):979-84. PubMed ID: 23998597
[TBL] [Abstract][Full Text] [Related]
18. Mobilization and engraftment of peripheral blood stem cells in healthy related donors >55 years old.
Motlló C; Sancho JM; Grífols JR; Juncà J; Morgades M; Ester A; Rodríguez I; Vives S; Batlle M; Guardia R; Ferrà C; Gallardo D; Millá F; Feliu E; Ribera JM
Cytotherapy; 2014 Mar; 16(3):406-11. PubMed ID: 24176544
[TBL] [Abstract][Full Text] [Related]
19. [Autologous peripheral blood stem cells mobilization with etoposide plus rhG-CSF versus cyclophosphamide plus rhG-CSF].
Shi YK; He XH; Han XH; Liu P; Yang JL; Zhou SY; Zhou AP; Zhang CG; Ai B
Ai Zheng; 2003 Dec; 22(12):1311-6. PubMed ID: 14693058
[TBL] [Abstract][Full Text] [Related]
20. Feasibility and cost analysis of day 4 granulocyte colony-stimulating factor mobilized peripheral blood progenitor cell collection from HLA-matched sibling donors.
Newell LF; Shoop KM; Knight RJ; Murray SN; Kwock RP; Jacoby CE; Slater S; Allen BE; Ottowa C; Cota B; Appel PL; Cook RJ; Maziarz RT; Meyers G
Cytotherapy; 2019 Jul; 21(7):725-737. PubMed ID: 31085121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
